The High-Stakes Race in CGT: Why Upstream Manufacturing Partners Matter More Than Ever

Cell and Gene Therapies (CGTs) represent one of the most transformative innovations in modern medicine, offering curative potential for previously untreatable diseases. Today, the CGT market is valued at $15.48 billion, and with breakthrough approvals, increased investment and a rapidly expanding pipeline, it is projected to grow to $28.9 billion by 2029 [1].

Access the Ebook

Complete the form below to access the full ebook.

"*" indicates required fields

Name*
Opt-in*

Back to List

Experience That Supports Your Goals

Every project begins with a clear understanding of the formulation, timeline, specifications, and production requirements. Technical expertise and collaborative planning help establish an effective manufacturing approach, supporting a seamless transition from product development through commercial production.

Request a Custom Quote